For instance, a whole-exome sequencing study of nivolumab-treated ccRCC cases found that patients experiencing clinical benefit from ICI were more likely to harbor PBRM-1 mutations (9/11 patients) compared to patients who experienced no clinical benefits (3/13 patients) [143]. This evidence concerns the gene PBRM1 and nonpapillary renal cell carcinoma.